Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07.

Kay L. Pogue-Geile,Nan Song,Patrick G. Gavin,Greg Yothers,S. Rim Kim,Nicole L. Johnson,Corey Lipchik,Carmen J. Allegra,Nicholas J. Petrelli,M. J. O'Connell,Norman Wolmark,Soonmyung Paik

Clinical outcome and benefit of oxaliplatin in colon cancer according to intrinsic subtypes: Results from NRG Oncology/NSABP C-07.

2016

Kay L. Pogue-Geile
Nan Song
Patrick G. Gavin
Greg Yothers
S. Rim Kim
Nicole L. Johnson
Corey Lipchik
Carmen J. Allegra
Nicholas J. Petrelli
M. J. O'Connell
Norman Wolmark
Soonmyung Paik

3510Background: In the C-07 trial for stage II/III colon cancer, oxaliplatin added to 5-fluorouracil + leucovorin (FULV) provided significant but modest absolute benefit for DFS. We hypothesized th...

Keywords:

Colorectal cancer
Oxaliplatin
Oncology
Medicine
Internal medicine
stage ii

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations